A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: The handling erythropoietin resistance with oxpentifylline (HERO) trial

American Journal of Kidney Diseases

Volumn 65, Issue 1, 2015, Pages 49-57

  Johnson, David W ^a,b,c   Pascoe, Elaine M ^a,z   Badve, Sunil V ^a,b   Dalziel, Kim ^d   Cass, Alan ^a,e   Clarke, Philip ^d   Ferrari, Paolo ^a,f   McDonald, Stephen P ^a,g   Morrish, Alicia T ^a,z   Pedagogos, Eugenie ^a,h   Perkovic, Vlado ^a,i   Reidlinger, Donna ^a,z   Scaria, Anish ^a,z   Walker, Rowan ^a,j   Vergara, Liza A ^a,z   Hawley, Carmel M ^a,b   D'Almeida, Emmanuel ^k   Fassett, Rob ^l   Kirkpatrick, Carl ^m   Phoon, Richard ⁿ   Tonkin, Andrew ^m   Forbes, Andrew ^m   Levin, Adeera ^o   Wheeler, David C ^p   Jardine, Meg ^q   Burman, Jenny ^q,t   Hand, Samantha ^q,t   Garvey, Leanne ^k   Suranyi, Michael ^r   Gilbert, Margaret ^r   Endre, Zoltan ^s   McNamara, Katheen ^s   Snelling, Paul ^t   Mahadevan, Kumar ^u   Pollock, Andrea ^u   Leary, Diana ^b   Ratanjee, Sharad ^l   Kirby, Julie ^l   Juneja, Rajiv ^v   Hill, Kathy ^v   Cook, Natasha ^w   Bisscheroux, Pascal ^w   McMahon, Lawrence ^x   Kent, Annette ^x   Raspudic, Matija ^h   Steinwandel, Uli ^f   Dogra, Sharan ^y   Pellicano, Susan ^y   Paul Brent, Peta Anne ^z   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f FREMANTLE HOSPITAL   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ King George V Building   (Australia)

^j ALFRED HOSPITAL   (Australia)

^k JOHN HUNTER HOSPITAL   (Australia)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^m MONASH UNIVERSITY   (Australia)

ⁿ WESTMEAD HOSPITAL   (Australia)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^q ANZAC Research Institute   (Australia)

^r LIVERPOOL HOSPITAL   (Australia)

^s Prince of Wales   (Australia)

^t ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^u NAMBOUR GENERAL HOSPITAL   (Australia)

^v FLINDERS MEDICAL CENTRE   (Australia)

^w AUSTIN HEALTH   (Australia)

^x BOX HILL HOSPITAL   (Australia)

^y SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^z Australasian Kidney Trials Network   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ERYTHROPOIETIN; HEMATOLOGIC AGENT; VASODILATOR AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY DISEASE; CONGENITAL DISORDER; CONTROLLED STUDY; COST CONTROL; DIABETES MELLITUS; DISABILITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; ENDOCRINE DISEASE; ERYTHROCYTE DISORDER; ERYTHROPOIESIS STIMULATING AGENT HYPORESPONSIVE ANEMIA; ESA RESISTANCE INDEX; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEMATOLOGIC DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IATROGENIC DISEASE; INDIGESTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SHORT FORM 36; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; VOMITING; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; DRUG POTENTIATION; DRUG RESISTANCE; ECONOMICS; ERYTHROPOIESIS; MIDDLE AGED; PROCEDURES; PSYCHOLOGY;

ADULT; AGED; ANEMIA; COST SAVINGS; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG RESISTANCE; DRUG SYNERGISM; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATOLOGIC AGENTS; HEMOGLOBINS; HUMANS; MIDDLE AGED; PENTOXIFYLLINE; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; VASODILATOR AGENTS;

EID: 84922433423     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.06.020     Document Type: Article

References (33)

1. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-1510
2. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesisstimulating agent hyporesponsiveness. Nephrology. 2007;12(4): 321-330
3. Badve SV, Hawley CM, Johnson DW. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology. 2011;16(2):144-153
4. Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W. Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease? Am J Kidney Dis. 2005;45(1):136-147
5. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44(5):866-876
6. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146-1155
7. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17(suppl 11):39-43
8. Badve SV, Beller EM, Cass A, et al. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev. 2013;8:CD006861
9. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994;83(2):262-267
10. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A. 2005;102(6):1906-1910
11. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9): 1271-1276
12. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093
13. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-2463
14. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806-7810
15. Semmler J, Gebert U, Eisenhut T, et al. Xanthine derivatives: Comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology. 1993;78(4):520-525
16. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15(7):1877-1882
17. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology. 2010;15(3):344-349
18. Mohammadpour AH, Nazemian F, Khaiat MH, et al. Evaluation of the effect of pentoxifylline on erythropoietinresistant anemia in hemodialysis patients. Saudi J Kidney Dis Transplant. 2014;25(1):73-78
19. Navarro JF, Mora C, Garcia J, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol. 1999;33(2): 121-125
20. Johnson DW, Hawley CM, Rosser B, et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial. BMC Nephrol. 2008;9:8
21. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032
22. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23-33
23. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology. 2004;9(4):223-228
24. Ware JE, Jr, Sherbourne CD. The MOS 36-Item Short- Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483
25. Australian Government Department of Health. Pharmaceutical benefits scheme. http://www.pbs.gov.au/pbs/home. Accessed September 17, 2013
26. Discount Chemist Warehouse. Search results. http://www.chemistwarehouse.com.au. Accessed September 17, 2013
27. Mortazavi M, Seyrafian S, Taheri S, et al. Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: A randomized clinical trial. Med Arhiv. 2012;66(2):84-86
28. Macdougall IC. Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients? Nephrol Dial Transplant. 2004;19(suppl 5):V73-V78
29. Locatelli F, Andrulli S, Memoli B, et al. Nutritionalinflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006;21(4):991-998
30. Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol. 2013;14:67
31. Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26(8):2641-2648
32. Bock HA, Hirt-Minkowski P, Brunisholz M, et al. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant. 2008;23(1):301-308
33. Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53(5):823-834.